Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 8Neoplasms 4Prostate Cancer Metastatic 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Solid Cancer 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Malignant Solid Tumor - Malignant Nervous System Neoplasm 1Lymphadenopathy 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × XRP6258 × Clear all
NCT01594918 2017-07-21

Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer

University of California, San Francisco

Phase 1 Completed
25 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡